Getting a Read on the EU’s Biosimilar Uptake Across Therapeutic Areas

Posted by Christina Corridon on May 31, 2018 8:00:00 AM

Laura Nielsen co-authored this blog post with Christina Corridon. 

Since the first EU biosimilar approval for Sandoz’s Omnitrope 12 years ago, the European biosimilar market has been difficult to predict. The dynamic policy and regulatory environment, differing levels of payer control, and variability in go-to-market approaches and manufacturing necessitate a bit of guesswork when it comes to predicting how a given biosimilar will perform. 


>
Read More